Prognostic effect of pretreatment serum carcinoembryonic antigen level: A useful tool for prediction of distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and total mesorectal excision

Chang Hyun Kim, Soo Young Lee, Hyeong Rok Kim, Young Jin Kim, Sergio Huerta

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Many studies have reported the prognostic value of pretreatment serum carcinoembryonic antigen (pre-CEA) levels on colorectal cancer outcomes. However, controversy remains concerning the significance of pre-CEA levels in patients with rectal cancer treated with neoadjuvant chemoradiotherapy (CRT). Our aim in this study was to investigate the prognostic role of the pre-CEA level in patients with locally advanced rectal cancer undergoing neoadjuvant CRT followed by total mesorectal excision (TME). A total of 419 patients with stages II and III rectal cancer treated with neoadjuvant CRT followed by TME with available pre-CEA data were included. The outcomes studied were 5-year local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and disease-free survival (DFS). Optimal pre-CEA cutoff values to predict DMFS were determined based on current smoking history. The median pre-CEA level of smokers was 3.8 ng/mL, and that of nonsmokers was 2.8 ng/mL (P

Original languageEnglish (US)
Article numbere1291
JournalMedicine
Volume94
Issue number31
DOIs
StatePublished - Aug 1 2015

Fingerprint

Carcinoembryonic Antigen
Chemoradiotherapy
Rectal Neoplasms
Neoplasm Metastasis
Serum
Survival
Disease-Free Survival
Colorectal Neoplasms
Smoking
History
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{dcf614366fec4e01a43b45c9ba32c379,
title = "Prognostic effect of pretreatment serum carcinoembryonic antigen level: A useful tool for prediction of distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and total mesorectal excision",
abstract = "Many studies have reported the prognostic value of pretreatment serum carcinoembryonic antigen (pre-CEA) levels on colorectal cancer outcomes. However, controversy remains concerning the significance of pre-CEA levels in patients with rectal cancer treated with neoadjuvant chemoradiotherapy (CRT). Our aim in this study was to investigate the prognostic role of the pre-CEA level in patients with locally advanced rectal cancer undergoing neoadjuvant CRT followed by total mesorectal excision (TME). A total of 419 patients with stages II and III rectal cancer treated with neoadjuvant CRT followed by TME with available pre-CEA data were included. The outcomes studied were 5-year local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and disease-free survival (DFS). Optimal pre-CEA cutoff values to predict DMFS were determined based on current smoking history. The median pre-CEA level of smokers was 3.8 ng/mL, and that of nonsmokers was 2.8 ng/mL (P",
author = "Kim, {Chang Hyun} and Lee, {Soo Young} and Kim, {Hyeong Rok} and Kim, {Young Jin} and Sergio Huerta",
year = "2015",
month = "8",
day = "1",
doi = "10.1097/MD.0000000000001291",
language = "English (US)",
volume = "94",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "31",

}

TY - JOUR

T1 - Prognostic effect of pretreatment serum carcinoembryonic antigen level

T2 - A useful tool for prediction of distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and total mesorectal excision

AU - Kim, Chang Hyun

AU - Lee, Soo Young

AU - Kim, Hyeong Rok

AU - Kim, Young Jin

AU - Huerta, Sergio

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Many studies have reported the prognostic value of pretreatment serum carcinoembryonic antigen (pre-CEA) levels on colorectal cancer outcomes. However, controversy remains concerning the significance of pre-CEA levels in patients with rectal cancer treated with neoadjuvant chemoradiotherapy (CRT). Our aim in this study was to investigate the prognostic role of the pre-CEA level in patients with locally advanced rectal cancer undergoing neoadjuvant CRT followed by total mesorectal excision (TME). A total of 419 patients with stages II and III rectal cancer treated with neoadjuvant CRT followed by TME with available pre-CEA data were included. The outcomes studied were 5-year local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and disease-free survival (DFS). Optimal pre-CEA cutoff values to predict DMFS were determined based on current smoking history. The median pre-CEA level of smokers was 3.8 ng/mL, and that of nonsmokers was 2.8 ng/mL (P

AB - Many studies have reported the prognostic value of pretreatment serum carcinoembryonic antigen (pre-CEA) levels on colorectal cancer outcomes. However, controversy remains concerning the significance of pre-CEA levels in patients with rectal cancer treated with neoadjuvant chemoradiotherapy (CRT). Our aim in this study was to investigate the prognostic role of the pre-CEA level in patients with locally advanced rectal cancer undergoing neoadjuvant CRT followed by total mesorectal excision (TME). A total of 419 patients with stages II and III rectal cancer treated with neoadjuvant CRT followed by TME with available pre-CEA data were included. The outcomes studied were 5-year local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and disease-free survival (DFS). Optimal pre-CEA cutoff values to predict DMFS were determined based on current smoking history. The median pre-CEA level of smokers was 3.8 ng/mL, and that of nonsmokers was 2.8 ng/mL (P

UR - http://www.scopus.com/inward/record.url?scp=84942414645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942414645&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000001291

DO - 10.1097/MD.0000000000001291

M3 - Article

C2 - 26252304

AN - SCOPUS:84942414645

VL - 94

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 31

M1 - e1291

ER -